MB-103 / Fortress - LARVOL DELTA

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

IO biomarker • Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • HER-2

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: City of Hope Medical Center | Recruiting ➔ Active, not recruiting | N=39 ➔ 24 | Trial completion date: Mar 2025 ➔ Feb 2026 | Trial primary completion date: Mar 2025 ➔ Feb 2026

Enrollment change • Enrollment closed • IO biomarker • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CTCs • HER-2

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Nov 2024 ➔ Jun 2025 | Trial primary completion date: Nov 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor • HER-2

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jun 2024 ➔ Nov 2024 | Trial primary completion date: Jun 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • HER-2

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2023 ➔ Feb 2025 | Trial primary completion date: Dec 2023 ➔ Feb 2025

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • HER-2

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2023 ➔ Dec 2023 | Trial primary completion date: Aug 2023 ➔ Dec 2023

CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CTCs • HER-2

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates (GlobeNewswire) - "Mustang will discontinue development of its MB-102, its CD123-targeted CAR T cell therapy, as well as its HER2-, CS1- and PSCA-targeted CAR T cell therapy programs, comprising a portion of the Company’s portfolio of CAR T cell therapies being developed by the Company in partnership with City of Hope."

Discontinued • Acute Myelogenous Leukemia • Bladder Cancer • Brain Cancer • Breast Cancer • CNS Tumor • Gastric Cancer • Genito-urinary Cancer • Glioblastoma • Glioma • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Leukemia • Multiple Myeloma • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Urothelial Cancer

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov) - P1; N=39; Recruiting; Sponsor: City of Hope Medical Center; Trial completion date: Aug 2021 ➔ Aug 2023; Trial primary completion date: Aug 2021 ➔ Aug 2023

CAR T-Cell Therapy • Clinical • IO biomarker • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CTCs • HER-2 • MRI

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: City of Hope Medical Center; Trial completion date: Jun 2021 ➔ Dec 2023; Trial primary completion date: Jun 2021 ➔ Dec 2023

Clinical • IO biomarker • Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Glioma • Immune Modulation • Inflammation • Oncology • Solid Tumor • HER-2

[VIRTUAL] MBP103 - Phase Separation in Microbiology: Considerations for the New "Blob-ology" (WMF 2021) - "If the prospective learner has long ignored the "flexible linkers" in your work because they are hard to purify, they aggregate or they do not have a structure, they will find this track hub useful. Upon completion of this Track Hub, the participant should be able to: Examine how disordered protein sequences give rise to tunable properties Define an experimental framework for decoding the function of protein condensates formed by liquid liquid phase separation in bacteria Identify erroneous interpretations of diffusion pertaining to protein phase separation and how to avoid them"

Mustang Bio reports third quarter 2019 financial results and recent corporate highlights (Mustang Bio) - "'We look forward to a strong presence at the upcoming 61st American Society of Hematology (ASH) Annual Meeting, where additional data pertaining to MB-107 (lentiviral gene therapy) and information pertaining to MB-106 (CD20-targeted CAR T cell therapy) will be presented. With a strong balance sheet and the continued advancement of our gene therapy and CAR T programs, we are well positioned to execute on our goals for the rest of 2019 and into 2020.'"

Clinical

Mustang Bio announces $9.28 million grant to fund phase 1 trial OF CAR T therapy MB-103 in HER2-positive breast cancer with brain metastases (GlobeNewswire) - “Mustang Bio, Inc….announced that City of Hope has received a $9.28 million grant from the California Institute for Regenerative Medicine (CIRM) to fund an ongoing Phase 1 clinical trial of MB-103 (HER2-specific CAR T cells) for the treatment of HER2-positive breast cancer with brain metastases.”

Financing